BioNTech Company Insiders

BNTX Stock

USD 94.86 4.32 4.77%

BioNTech employs about 7.8 K people. The company is managed by 26 executives with a total tenure of roughly 18217 years, averaging almost 700.0 years of service per executive, having 300.27 employees per reported executive. Management-performance analysis for BioNTech SE gives investors another way to evaluate how leadership is influencing execution, capital allocation, and operating discipline. That matters because management quality often influences how well a company responds when business conditions become less favorable.

Build portfolio with BioNTech Stock

BioNTech's Workforce Through the Years

Historical employee data for BioNTech can give investors another way to assess whether the business is scaling, restructuring, or stabilizing across different operating conditions. Based on the current model, BioNTech is expected to maintain about 7,810 employees by April 2026.

Macro event markers

Covid

Interest Hikes

Management Team Effectiveness

The company has return on total asset (ROA) of -3.56 % meaning that the return on assets was negative, reflecting a $3.56 loss per $100. This sits far below comparable companies. Similarly, it shows a return on stockholder's equity (ROE) of -5.88 %, suggesting that it is drawing down equity without generating offsetting profit.

Per market data dated March 18, 2026, Net Income Applicable To Common Shares is projected to grow to approximately 12.4 B, whereas our analysis places Common Stock Shares Outstanding near about 236.3 M following downward revisions.

Stock Institutional Investors

Institutions hold about 19.61% of BioNTech SE while insiders own roughly 55.13%. Current market capitalization is about 22.75 Billion. At that level, retail participation has a bigger role in day-to-day price moves. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. With moderate institutional presence, retail activity has more room to move the price day to day.

		Shares
Blackrock Inc	2025-09-30	765.3 K
Franklin Resources Inc	2025-09-30	732.8 K
Citadel Advisors Llc	2025-12-31	678.2 K
Ubs Group Ag	2025-09-30	607.4 K
Candriam Luxembourg S.c.a.	2025-12-31	604.9 K
Morgan Stanley - Brokerage Accounts	2025-09-30	603 K
Bank Of America Corp	2025-09-30	573.4 K
Bank Of New York Mellon Corp	2025-09-30	568.7 K
Long Focus Capital Management, Llc	2025-12-31	507.7 K
Fmr Inc	2025-12-31	5.9 M
T. Rowe Price Investment Management,inc.	2025-09-30	4.8 M

BioNTech SE mid-cap profile at 22.75 Billion shapes market structure and potential liquidity pressure during stressed periods. Whether BioNTech SE institutional base is index-driven or conviction-based changes how to read it - at this size active managers often hold meaningful weight.

Outstanding Bonds

BioNTech SE may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Longer-dated obligations can improve financing stability, but they also leave investors more exposed if the underlying business weakens before the debt matures.

MGM Resorts International Corp Bond

US552953CD18

View

View All BioNTech Corporate Bonds

Corporate Filings

6K	10th of March 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	28th of January 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	14th of January 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	12th of January 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	6th of January 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	18th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	9th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
6K	8th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify

BioNTech displays a noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Insider ownership stands at approximately 55% while institutional investors account for 20%, leaving 25% of the float in public hands.

Shares in Circulation

First Issued

2018-03-31

Previous Quarter

239.2 M

Current Value

245.2 M

Average Shares Outstanding

239 M

Quarterly Volatility

16.1 M

Macro event markers

Covid

Interest Hikes

Holders Distribution

For BioNTech SE, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. The opportunity for retail investors is not to imitate blindly, but to understand how large-holder positioning may affect liquidity, volatility, and timing.

Market Cap and Value

Market Cap Enterprise Value

Workforce Comparison

BioNTech SE is rated fifth in number of employees among leading competitors. The total workforce of Health Care industry is currently estimated at about 149,804. BioNTech holds roughly 7,807 in number of employees claiming about 5% of equities under Health Care sector.

Workforce Valuation Capitalization Revenue Total debt

Compare BioNTech to Competition

The company has Profit Margin (PM) of -40.0 %, which suggests pricing discipline or cost control requires further improvement. This sits far below comparable companies. Similarly, it shows Operating Margin (OM) of -33.0 %, which implies that the company is operating at a deficit of $33.0 per $100 of sales.

Benchmark Summation

Operator

This analysis covers sixty-one data points across the selected time horizon. BioNTech SE Price Series Summation is a cross summation of BioNTech price series and its benchmark/peer.

Notable Stakeholders

Reviewing the stakeholders around BioNTech can help investors understand which people or institutions may influence direction, governance, and strategic pressure. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.

Pr MD	CoFounder Board	Profile
Ugur MD	CEO CoFounder	Profile
Ramn ZapataGomez	CFO Board	Profile
Ramon ZapataGomez	CFO Board	Profile
Sierk Ptting	COO MD	Profile
Katalin Kariko	Senior Therapies	Profile
Jens Holstein	CFO Board	Profile
Michael Boehler	MD Communications	Profile
Siegbert Kloos	Datand Digital	Profile
Beate Berns	Senior Resources	Profile
Sierk Poetting	COO MD	Profile
Sean Marett	Executive Officer	Profile
Oliver Hennig	Senior Operations	Profile
Lisa Birringer	Senior Accounting	Profile
Jasmina Alatovic	Vice Communications	Profile
Andreas Kuhn	Senior Manufacturing	Profile
James Ryan	Chief Board	Profile
Annemarie Hanekamp	Chief Board	Profile
Sylke Maas	Vice Strategy	Profile
Douglas Maffei	Vice Relations	Profile
Kylie Jimenez	Chief Board	Profile
Zach Taylor	Senior Strategy	Profile
Ozlem MD	Chief CoFounder	Profile
Oliver Henning	Senior Operations	Profile
Ryan Richardson	MD Officer	Profile
Sebastian MD	Senior Research	Profile

Management Information & Data Sources

BioNTech is a large-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Management quality is often reflected indirectly through margin durability, reinvestment choices, and governance signals. CEO is Ugur MD with 7,807 employees and 26 reported executives.

Unless otherwise specified, data for BioNTech SE is compiled from periodic company reporting and market reference feeds and standardized for comparability. Sell-side coverage, where present, supplements the data shown. Updates may occur throughout the day. Insider and management fields are mapped from published filings and company disclosures.

This content is curated and reviewed by:

Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board

Last reviewed on March 1st, 2026

Workforce Efficiency and Productivity

Workforce efficiency at BioNTech SE can help investors judge how effectively labor resources are being converted into revenue and profit over time. The business is commonly classified in the Healthcare sector and the Biotechnology industry.

BioNTech Manpower Efficiency

Return on BioNTech Manpower

	Revenue Per Employee	353.1K
	Revenue Per Executive	106M
	Net Loss Per Employee	139.8K
	Net Loss Per Executive	42M
	Working Capital Per Employee	1.8M
	Working Capital Per Executive	538.6M

Popular Tools for BioNTech Stock analysis

	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC